A health-intelligence giant that helps drugmakers run clinical trials, sell their medicines, and make sense of huge piles of healthcare data—drawing on a trove covering roughly nine in ten of the world's pharmaceuticals. It was born in 2016 when Quintiles, the contract-research firm founded by a statistics professor in 1982, merged with IMS Health, a market-data company from 1954. Its name blends letters from both: the "I" from IMS and "Q" from Quintiles, plus "VIA" for the road ahead.
Q2 2026 revenue rose 8.4% to $4.15B while R&D Solutions profit dipped 0.8%
R&D Solutions profit dipped as cost of revenues outran its growth. rose 8.4% to $4,151M and rose 15% to $1.61, with both new segments growing but climbing to $51M. The company entered its two- structure with growth intact and margin pressure from compensation costs.
Key takeaways
R&D Solutions edged down 0.8% as cost of revenues rose 8.0%, even as clinical and lab volume lifted its 6.2% (4.2% ) in Q1 2026.
Consolidated rose 8.4% (6.0% ) to $4,151M in Q1 2026, led by up 11.6% and R&D Solutions up 6.2% under the new two- structure effective January 1, 2026.
rose 15% to $1.61 and rose 10% to $274M; was 32.6%, down 1.3 points from a year earlier.
Section summaries
Management's Discussion and Analysis
IQVIA Q2 2026 revenue rose 8.7% to $4.37B driven by growth in both Commercial and R&D Solutions segments.
⌄
Total Q2 2026 revenues grew 8.7% to $4,368 million, with growth of 8.5%.
Q2 increased 8.8% to $2,575 million, driven by volume-related growth in clinical services and lab testing.
rose to $51M from $29M a year ago for ongoing global streamlining planned through 2026, and increased to $192M on higher debt balances.
improved $50M to $618M and the company repurchased $552M in stock, ending with $1,947M in cash.
The company reorganized into two segments — and R&D Solutions — effective January 1, 2026, with this quarter reported under the new split.
What changed
Q2 2026 R&D Solutions was flagged to watch after the 0.8% Q1 dip; the new two- structure began January 1, 2026, and Q1 shows the dip persisted at 0.8% rather than deepening.
was flagged to watch given $14.0B and $2B 6.25% notes issued in 2025; Q1 2026 interest expense rose to $192M on higher debt balances.
were flagged to watch as 2025 actions continued through 2026; Q1 2026 costs rose to $51M from $29M a year ago under streamlining planned through 2026.
growth was flagged after its 11.6% Q1 rise under the new structure; Q1 2026 shows 11.6% growth as the first reported quarter under the two- split.
FY2025 10-K flagged Q1 2026 reporting under the new two- structure versus the prior three-segment split; the reorganization into and R&D Solutions took effect January 1, 2026.
What to watch
Q2 2026 R&D Solutions to see if the 0.8% decline deepens or reverses as converts from the $32.7B year-end level.
Q2 2026 given $14.0B and the $2B 6.25% notes issued in 2025.
Q2 2026 as the $51M Q1 figure reflects streamlining planned through 2026.
Q2 2026 growth to confirm the 11.6% Q1 rise holds under the new structure.
Q2 increased 8.6% to $1,793 million, led by growth in patient solutions and commercial engagement services.
Consolidated cost of revenues, excluding D&A, rose 8.9% to $2,933 million, primarily due to higher compensation and reimbursed expenses to support growth.
doubled to $63 million in Q2 2026 as the company streamlines global operations, with actions expected through 2027.
increased $165 million to $1,176 million in H1 2026, while the company repurchased $950 million in stock and issued €950 million in new senior notes.
Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes to our quantitative and qualitative disclosures about market risk as compared to the quantitative and qualitative disclosures about market risk described in our 2025 Form 10-K.
⌄
There have been no material changes to our quantitative and qualitative disclosures about market risk as compared to the quantitative and qualitative disclosures about market risk described in our 2025 Form 10-K.
We are party to legal proceedings incidental to our business. While the outcome of these matters could differ from management’s expectations, we do not believe that the resolution of these matters is reasonably likely to have a material adverse effect to our financial statements…
⌄
We are party to legal proceedings incidental to our business. While the outcome of these matters could differ from management’s expectations, we do not believe that the resolution of these matters is reasonably likely to have a material adverse effect to our financial statements.
Information pertaining to legal proceedings can be found in Note 8 to the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q and is incorporated by reference herein.
For a discussion of the risks relating to our business, see Part I—Item 1A—“Risk Factors” of our 2025 Form 10-K. There have been no material changes from the risk factors previously disclosed in our 2025 Form 10-K.
⌄
For a discussion of the risks relating to our business, see Part I—Item 1A—“Risk Factors” of our 2025 Form 10-K. There have been no material changes from the risk factors previously disclosed in our 2025 Form 10-K.